| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.97 | 0 | 0.97 | Lanosterol 14 alpha demethylase inhibitor | 0.851 0.001 DB11633 | ||
| 0.771 | 0.003 | 0.771 | P-glycoprotein inhibitor | 0.286 0.032 DB11633 | ||
| 0.198 | 0.03 | 0.483 | Cell wall synthesis inhibitor | 0.483 0.004 DB11633 0.295 0.01 DBMET03759 | DB11633 | |
| 0.166 | 0.019 | 0.664 | Breast cancer-resistant protein inhibitor | 0.664 0.004 DB11633 | DB11633 | |
| 0.081 | 0.099 | 0.129 | Alpha 2d adrenoreceptor antagonist | 0.129 0.017 DB11633 | DB11633 | |
| 0.069 | 0.14 | 0.159 | M18 aspartyl aminopeptidase inhibitor | 0.159 0.048 DB11633 | DB11633 | |
| 0.06 | 0.196 | 0.134 | Toll-Like receptor 3 antagonist | 0.134 0.021 DBMET03759 | DBMET03759 | |
| 0.06 | 0.231 | 0.132 | Hedgehog signaling inhibitor | 0.132 0.032 DB11633 | DB11633 | |
| 0.116 | 0.342 | 0.302 | Sodium/bile acid cotransporter inhibitor | 0.302 0.077 DBMET03759 | DBMET03759 | |
| 0.008 | 0.235 | 0.046 | Nicotinic acid receptor 2 agonist | 0.046 0.016 DBMET03759 | DBMET03759 | |
| 0.023 | 0.285 | 0.076 | Glutamate (mGluR) antagonist | 0.076 0.054 DB11633 | DB11633 | |
| 0.042 | 0.327 | 0.091 | Transcription factor NF kappa B stimulant | 0.091 0.049 DBMET03759 | DBMET03759 | |
| 0.029 | 0.35 | 0.082 | Uric acid excretion stimulant | 0.082 0.08 DBMET03759 | DBMET03759 | |
| 0.013 | 0.353 | 0.084 | HIV-1 reverse transcriptase inhibitor | 0.084 0.039 DBMET03758 | DBMET03758 | |
| 0.009 | 0.353 | 0.159 | Glutamate (mGluR) agonist | 0.159 0.013 DBMET03758 0.065 0.04 DB11633 | DBMET03758 | |
| 0.125 | 0.487 | 0.39 | Calcium channel L-type activator | 0.39 0.088 DBMET03759 | DBMET03759 | |
| 0.038 | 0.413 | 0.135 | MAP3K9 inhibitor | 0.135 0.085 DBMET03759 | DBMET03759 | |
| 0.034 | 0.413 | 0.117 | Interleukin 5 antagonist | 0.117 0.026 DBMET03759 | DBMET03759 | |
| 0.017 | 0.408 | 0.066 | Cyclin H inhibitor | 0.066 0.032 DBMET03759 | DBMET03759 | |
| 0.068 | 0.46 | 0.159 | Growth factor agonist | 0.159 0.122 DBMET03759 | DBMET03759 | |
| 0.063 | 0.472 | 0.163 | Lipocortins synthesis antagonist | 0.163 0.088 DBMET03759 | DBMET03759 | |
| 0.019 | 0.434 | 0.086 | Protein kinase C mu inhibitor | 0.086 0.072 DBMET03759 | DBMET03759 | |
| 0.031 | 0.46 | 0.323 | Hypolipemic | 0.323 0.042 DBMET03758 | DBMET03758 | |
| 0.08 | 0.536 | 0.153 | CC chemokine 6 receptor antagonist | 0.153 0.018 DBMET03759 | DBMET03759 | |
| 0.004 | 0.466 | 0.024 | Integrin alphaVbeta3 antagonist | 0.024 0.012 DBMET03759 | DBMET03759 | |
| 0.085 | 0.549 | 0.226 | Peptidyltransferase inhibitor | 0.226 0.07 DBMET03759 | DBMET03759 | |
| 0.046 | 0.522 | 0.199 | Immunosuppressant | 0.199 0.198 DBMET03759 | DBMET03759 | |
| 0.065 | 0.542 | 0.633 | Analgesic | 0.633 0.021 DBMET03758 0.273 0.163 DBMET03759 | DBMET03758 | |
| 0.013 | 0.501 | 0.048 | 5 Hydroxytryptamine 1B agonist | 0.048 0.046 DBMET03758 | DBMET03758 | |
| 0.008 | 0.506 | 0.084 | TIE antagonist | 0.084 0.055 DBMET03759 | DBMET03759 | |
| 0.008 | 0.507 | 0.082 | TIE-2 antagonist | 0.082 0.055 DBMET03759 | DBMET03759 | |
| 0.007 | 0.533 | 0.052 | Mineralocorticoid receptor antagonist | 0.052 0.028 DBMET03758 | DBMET03758 | |
| 0.094 | 0.636 | 0.259 | MAP kinase kinase 3 inhibitor | 0.259 0.024 DBMET03759 | DBMET03759 | |
| 0.039 | 0.582 | 0.124 | NOS3 expression enhancer | 0.124 0.107 DBMET03759 | DBMET03759 | |
| 0.009 | 0.555 | 0.061 | CDK1/cyclin B1 inhibitor | 0.061 0.059 DBMET03759 | DBMET03759 | |
| 0.051 | 0.604 | 0.165 | MAP-kinase-activated kinase 5 inhibitor | 0.165 0.157 DBMET03759 | DBMET03759 | |
| 0.038 | 0.6 | 0.09 | Folate antagonist | 0.09 0.086 DBMET03759 | DBMET03759 | |
| 0.011 | 0.577 | 0.092 | Topoisomerase I inhibitor | 0.092 0.078 DBMET03758 | DBMET03758 | |
| 0.005 | 0.573 | 0.052 | Acetyl-CoA transferase inhibitor | 0.052 0.038 DBMET03758 | DBMET03758 | |
| 0.035 | 0.621 | 0.078 | Transforming growth factor beta 3 antagonist | 0.078 0.074 DBMET03759 | DBMET03759 | |
| 0.031 | 0.625 | 0.24 | Ca2+/calmodulin-dependent protein kinase kinase B inhibitor | 0.239 0.007 DBMET03758 0.24 0.007 DBMET03759 | DBMET03759 | |
| 0.037 | 0.636 | 0.472 | Toll-Like receptor 7 agonist | 0.472 0.038 DBMET03759 | DBMET03759 | |
| 0.036 | 0.64 | 0.48 | Toll-Like receptor agonist | 0.48 0.036 DBMET03759 | DBMET03759 | |
| 0.008 | 0.612 | 0.081 | Phosphodiesterase 3A inhibitor | 0.081 0.054 DBMET03758 | DBMET03758 | |
| 0.025 | 0.629 | 0.103 | Activin receptor-like kinase 4 inhibitor | 0.103 0.08 DBMET03759 | DBMET03759 | |
| 0.004 | 0.612 | 0.051 | Glutamate (mGluR2) agonist | 0.051 0.013 DBMET03758 | DBMET03758 | |
| 0.005 | 0.62 | 0.054 | Glutamate (mGluR group II) agonist | 0.054 0.014 DBMET03758 | DBMET03758 | |
| 0.021 | 0.642 | 0.055 | Kallikrein 1 inhibitor | 0.055 0.041 DBMET03758 | DBMET03758 | |
| 0.008 | 0.631 | 0.1 | Protein kinase C delta inhibitor | 0.1 0.052 DBMET03759 | DBMET03759 | |
| 0.013 | 0.637 | 0.122 | Cyclin-dependent kinase 7 inhibitor | 0.122 0.083 DBMET03759 | DBMET03759 | |
| 0.062 | 0.687 | 0.155 | MAP kinase kinase 5 inhibitor | 0.155 0.134 DBMET03759 | DBMET03759 | |
| 0.037 | 0.662 | 0.289 | Immunomodulator | 0.289 0.089 DBMET03759 | DBMET03759 | |
| 0.013 | 0.639 | 0.093 | Chelator | 0.093 0.087 DBMET03759 | DBMET03759 | |
| 0.051 | 0.679 | 0.61 | Antiinflammatory | 0.458 0.106 DBMET03758 0.61 0.051 DBMET03759 | DBMET03759 | |
| 0.008 | 0.639 | 0.162 | CDC-like kinase 4 inhibitor | 0.162 0.091 DBMET03759 | DBMET03759 | |
| 0.028 | 0.664 | 0.103 | Hematopoietic | 0.103 0.032 DBMET03759 | DBMET03759 | |
| 0.005 | 0.643 | 0.052 | Integrin alpha5beta1 antagonist | 0.052 0.017 DBMET03759 | DBMET03759 | |
| 0.006 | 0.652 | 0.127 | Glutamate receptor antagonist | 0.127 0.067 DBMET03759 | DBMET03759 | |
| 0.007 | 0.66 | 0.132 | CDC-like kinase 2 inhibitor | 0.132 0.108 DBMET03759 | DBMET03759 | |
| 0.005 | 0.661 | 0.036 | Purinergic P2Y14 antagonist | 0.036 0.014 DBMET03759 | DBMET03759 | |
| 0.005 | 0.664 | 0.149 | Clk dual-specificity kinase inhibitor | 0.149 0.115 DBMET03759 | DBMET03759 | |
| 0.036 | 0.698 | 0.298 | Cyclophilin D inhibitor | 0.298 0.164 DBMET03759 | DBMET03759 | |
| 0.018 | 0.683 | 0.105 | Antineoplastic alkaloid | 0.105 0.044 DBMET03758 | DBMET03758 | |
| 0.008 | 0.674 | 0.065 | MAP3K7 inhibitor | 0.065 0.063 DBMET03759 | DBMET03759 | |
| 0.051 | 0.723 | 0.154 | Cyclin-dependent kinase 3 inhibitor | 0.154 0.086 DBMET03759 | DBMET03759 | |
| 0.04 | 0.715 | 0.161 | MAP kinase kinase 4 inhibitor | 0.161 0.043 DBMET03759 | DBMET03759 | |
| 0.003 | 0.691 | 0.302 | Aromatase inhibitor | 0.302 0.005 DB11633 | DB11633 | |
| 0.003 | 0.691 | 0.023 | Retinoid X gamma receptor agonist | 0.023 0.017 DBMET03759 | DBMET03759 | |
| 0.011 | 0.7 | 0.155 | I kappa B kinase 1 inhibitor | 0.155 0.009 DBMET03759 | DBMET03759 | |
| 0.021 | 0.711 | 0.149 | Aurora-C kinase inhibitor | 0.149 0.052 DBMET03759 | DBMET03759 | |
| 0.006 | 0.704 | 0.143 | Protein-tyrosine phosphatase inhibitor | 0.143 0.086 DBMET03759 | DBMET03759 | |
| 0.003 | 0.706 | 0.019 | Integrin beta5 antagonist | 0.019 0.017 DBMET03759 | DBMET03759 | |
| 0.008 | 0.711 | 0.157 | Phosphodiesterase inhibitor | 0.157 0.054 DBMET03758 | DBMET03758 | |
| 0.005 | 0.709 | 0.043 | Retinoic acid alpha receptor agonist | 0.043 0.021 DBMET03759 | DBMET03759 | |
| 0.007 | 0.713 | 0.042 | DNA topoisomerase IV inhibitor | 0.042 0.008 DBMET03759 | DBMET03759 | |
| 0.005 | 0.711 | 0.154 | Dual specificity tyrosine-phosphorylation regulated kinase 1A inhibitor | 0.154 0.127 DBMET03759 | DBMET03759 | |
| 0.005 | 0.714 | 0.292 | Phosphodiesterase III inhibitor | 0.292 0.004 DBMET03758 | DBMET03758 | |
| 0.009 | 0.732 | 0.266 | Potassium channel blocker | 0.266 0.059 DBMET03758 | DBMET03758 | |
| 0.005 | 0.728 | 0.145 | Dyrk kinase inhibitor | 0.145 0.141 DBMET03759 | DBMET03759 | |
| 0.022 | 0.748 | 0.173 | Interleukin 4 antagonist | 0.173 0.033 DBMET03759 | DBMET03759 | |
| 0.01 | 0.745 | 0.162 | Ca2+/calmodulin-dependent protein kinase inhibitor | 0.134 0.132 DBMET03758 0.162 0.102 DBMET03759 | DBMET03759 | |
| 0.015 | 0.757 | 0.063 | Adenine nucleotide translocase inhibitor | 0.063 0.023 DBMET03759 | DBMET03759 | |
| 0.005 | 0.748 | 0.172 | GABA A receptor agonist | 0.172 0.013 DB11633 | DB11633 | |
| 0.018 | 0.763 | 0.092 | Phosphodiesterase 7B inhibitor | 0.092 0.066 DBMET03759 | DBMET03759 | |
| 0.004 | 0.75 | 0.063 | Neuropeptide Y5 antagonist | 0.063 0.028 DBMET03758 | DBMET03758 | |
| 0.012 | 0.759 | 0.05 | Factor III inhibitor | 0.05 0.034 DBMET03759 | DBMET03759 | |
| 0.005 | 0.756 | 0.135 | DNA gyrase inhibitor | 0.135 0.01 DBMET03759 | DBMET03759 | |
| 0.005 | 0.769 | 0.312 | HERG channel blocker | 0.312 0.046 DBMET03758 | DBMET03758 | |
| 0.008 | 0.781 | 0.157 | Interleukin-1 receptor-associated protein kinase 1 inhibitor | 0.157 0.089 DBMET03758 0.132 0.112 DBMET03759 | DBMET03758 | |
| 0.007 | 0.783 | 0.197 | Death-associated protein kinase 3 inhibitor | 0.197 0.076 DBMET03759 | DBMET03759 | |
| 0.005 | 0.786 | 0.111 | Ca2+/calmodulin-dependent kinase II delta inhibitor | 0.111 0.092 DBMET03759 | DBMET03759 | |
| 0.009 | 0.799 | 0.119 | Ca2+/calmodulin-dependent kinase II gamma inhibitor | 0.119 0.117 DBMET03759 | DBMET03759 | |
| 0.042 | 0.84 | 0.366 | MAP kinase kinase 6 inhibitor | 0.257 0.181 DBMET03758 0.366 0.081 DBMET03759 | DBMET03759 | |
| 0.009 | 0.807 | 0.095 | Dual specificity tyrosine-phosphorylation regulated kinase 2 inhibitor | 0.095 0.043 DBMET03759 | DBMET03759 | |
| 0.005 | 0.807 | 0.194 | GABA receptor agonist | 0.194 0.019 DB11633 | DB11633 | |
| 0.005 | 0.808 | 0.282 | Potassium channel (Voltage-sensitive) blocker | 0.282 0.055 DBMET03758 | DBMET03758 | |
| 0.003 | 0.827 | 0.115 | Amidase inhibitor | 0.115 0.017 DBMET03758 | DBMET03758 | |
| 0.036 | 0.866 | 0.132 | Death-associated protein kinase 1 inhibitor | 0.132 0.076 DBMET03758 | DBMET03758 | |
| 0.003 | 0.833 | 0.098 | Glutamate (mGluR1a) antagonist | 0.098 0.005 DBMET03759 | DBMET03759 | |
| 0.028 | 0.872 | 0.177 | Death-associated protein kinase 2 inhibitor | 0.177 0.058 DBMET03759 | DBMET03759 | |
| 0.008 | 0.856 | 0.469 | Cardiotonic | 0.469 0.019 DBMET03758 | DBMET03758 | |
| 0.001 | 0.854 | 0.043 | Vascular adhesion protein 1 inhibitor | 0.043 0.022 DBMET03758 | DBMET03758 | |
| 0.003 | 0.857 | 0.092 | Macrophage migration inhibitory factor inhibitor | 0.092 0.04 DBMET03758 | DBMET03758 | |
| 0.002 | 0.857 | 0.05 | Angiotensin II receptor antagonist | 0.05 0.007 DBMET03759 | DBMET03759 | |
| 0.012 | 0.869 | 0.19 | Nootropic | 0.19 0.172 DBMET03759 | DBMET03759 | |
| 0.002 | 0.863 | 0.139 | Glutamate (mGluR group I) agonist | 0.139 0.005 DBMET03758 | DBMET03758 | |
| 0.005 | 0.873 | 0.29 | Antibacterial | 0.214 0.213 DBMET03758 0.29 0.143 DBMET03759 | DBMET03759 | |
| 0.001 | 0.876 | 0.058 | Angiotensin AT1 receptor antagonist | 0.058 0.008 DBMET03759 | DBMET03759 | |
| 0.001 | 0.893 | 0.125 | Glutamate (mGluR5) agonist | 0.125 0.005 DBMET03758 | DBMET03758 | |
| 0.007 | 0.899 | 0.229 | Angiogenesis inhibitor | 0.229 0.139 DBMET03759 | DBMET03759 | |
| 0.003 | 0.896 | 0.026 | NMDA 2D receptor antagonist | 0.026 0.02 DBMET03759 | DBMET03759 | |
| 0.003 | 0.898 | 0.124 | Gastric antisecretory | 0.124 0.04 DBMET03759 | DBMET03759 | |
| 0.002 | 0.898 | 0.048 | Dopamine beta hydroxylase inhibitor | 0.048 0.035 DBMET03759 | DBMET03759 | |
| 0.003 | 0.9 | 0.049 | Oxytocin antagonist | 0.049 0.018 DBMET03758 | DBMET03758 | |
| 0.005 | 0.902 | 0.109 | Topoisomerase II inhibitor | 0.109 0.077 DBMET03759 | DBMET03759 | |
| 0.001 | 0.904 | 0.065 | Benzodiazepine agonist | 0.065 0.058 DBMET03758 | DBMET03758 | |
| 0.004 | 0.909 | 0.041 | Neuraminidase (Influenza A) inhibitor | 0.041 0.04 DBMET03759 | DBMET03759 | |
| 0.002 | 0.907 | 0.154 | Glutamate receptor agonist | 0.154 0.017 DBMET03758 0.094 0.042 DB11633 | DBMET03758 | |
| 0.008 | 0.913 | 0.177 | Interleukin 6 antagonist | 0.141 0.104 DBMET03758 0.177 0.057 DBMET03759 | DBMET03759 | |
| 0.006 | 0.911 | 0.058 | Prostaglandin F2 alpha antagonist | 0.058 0.05 DBMET03759 | DBMET03759 | |
| 0.005 | 0.914 | 0.288 | Tumour necrosis factor alpha release inhibitor | 0.288 0.058 DBMET03759 | DBMET03759 | |
| 0.001 | 0.911 | 0.157 | Protein kinase (CK2) alpha inhibitor | 0.157 0.038 DBMET03759 | DBMET03759 | |
| 0.004 | 0.92 | 0.085 | Xanthine oxidase inhibitor | 0.085 0.081 DBMET03759 | DBMET03759 | |
| 0.002 | 0.923 | 0.075 | CYP2A6 inhibitor | 0.075 0.054 DBMET03758 0.067 0.063 DBMET03759 | DBMET03758 | |
| 0.002 | 0.93 | 0.066 | Potassium channel (ATP-sensitive) blocker | 0.066 0.049 DBMET03759 | DBMET03759 | |
| 0.002 | 0.931 | 0.092 | Potassium channel intermediate-conductance Ca-activated blocker | 0.092 0.011 DBMET03758 0.055 0.053 DBMET03759 | DBMET03758 | |
| 0.001 | 0.937 | 0.081 | Rho-associated kinase I inhibitor | 0.081 0.045 DBMET03759 | DBMET03759 | |
| 0.001 | 0.938 | 0.157 | Glutamate (mGluR1) antagonist | 0.157 0.006 DBMET03759 | DBMET03759 | |
| 0.005 | 0.942 | 0.341 | Cholesterol antagonist | 0.341 0.068 DBMET03759 | DBMET03759 | |
| 0.001 | 0.939 | 0.159 | Protein kinase (CK2) inhibitor | 0.159 0.029 DBMET03759 | DBMET03759 | |
| 0.001 | 0.94 | 0.032 | HCV NS5B polymerase inhibitor | 0.032 0.021 DBMET03759 | DBMET03759 | |
| 0.001 | 0.94 | 0.075 | Geranyltranstransferase inhibitor | 0.075 0.005 DBMET03759 | DBMET03759 | |
| 0.001 | 0.941 | 0.082 | Dihydroorotate dehydrogenase inhibitor | 0.082 0.017 DBMET03759 | DBMET03759 | |
| 0.002 | 0.944 | 0.116 | Bcr-Abl kinase inhibitor | 0.116 0.029 DBMET03759 | DBMET03759 | |
| 0.002 | 0.946 | 0.333 | Mediator release inhibitor | 0.101 0.068 DBMET03758 0.333 0.006 DBMET03759 | DBMET03759 | |
| 0.001 | 0.944 | 0.037 | Diamine oxidase inhibitor | 0.037 0.026 DBMET03759 | DBMET03759 | |
| 0.001 | 0.945 | 0.02 | Hexokinase stimulant | 0.02 0.013 DBMET03759 | DBMET03759 | |
| 0.002 | 0.948 | 0.104 | Potassium channel activator | 0.104 0.044 DBMET03759 | DBMET03759 | |
| 0.006 | 0.953 | 0.089 | Glutamate (mGluR7) agonist | 0.089 0.086 DBMET03759 | DBMET03759 | |
| 0.002 | 0.95 | 0.061 | Lysine-specific demethylase 1A inhibitor | 0.061 0.027 DBMET03758 | DBMET03758 | |
| 0.002 | 0.951 | 0.338 | I kappa B kinase epsilon inhibitor | 0.338 0.005 DBMET03759 | DBMET03759 | |
| 0 | 0.95 | 0.014 | Angiotensin AT1B receptor antagonist | 0.014 0.009 DBMET03759 | DBMET03759 | |
| 0.001 | 0.953 | 0.073 | Syk tyrosine kinase inhibitor | 0.073 0.046 DBMET03759 | DBMET03759 | |
| 0.001 | 0.954 | 0.092 | Cyclin-dependent kinase 9 inhibitor | 0.092 0.073 DBMET03759 | DBMET03759 | |
| 0.002 | 0.958 | 0.291 | 15-Lipoxygenase inhibitor | 0.291 0.137 DBMET03759 | DBMET03759 | |
| 0.003 | 0.959 | 0.203 | Anticonvulsant | 0.203 0.08 DBMET03758 | DBMET03758 | |
| 0.001 | 0.958 | 0.064 | Xanthine dehydrogenase inhibitor | 0.064 0.035 DBMET03759 | DBMET03759 | |
| 0.004 | 0.962 | 0.117 | Aldehyde dehydrogenase inhibitor | 0.117 0.074 DBMET03759 | DBMET03759 | |
| 0.003 | 0.962 | 0.27 | Hypoxia-inducible factor 1 alpha inhibitor | 0.27 0.083 DBMET03759 | DBMET03759 | |
| 0.001 | 0.96 | 0.069 | Purinergic P2Y antagonist | 0.069 0.016 DBMET03759 | DBMET03759 | |
| 0.001 | 0.962 | 0.026 | Glucosylceramidase stimulant | 0.026 0.022 DBMET03759 | DBMET03759 | |
| 0.001 | 0.961 | 0.095 | Aurora-B kinase inhibitor | 0.095 0.089 DBMET03759 | DBMET03759 | |
| 0.001 | 0.962 | 0.049 | AMPA receptor antagonist | 0.049 0.032 DBMET03759 | DBMET03759 | |
| 0.001 | 0.963 | 0.099 | Caspase 7 inhibitor | 0.099 0.029 DBMET03759 | DBMET03759 | |
| 0.004 | 0.967 | 0.136 | Antibacterial (Helicobacter pylori) | 0.136 0.06 DBMET03759 | DBMET03759 | |
| 0.001 | 0.965 | 0.096 | Adenosine A3 receptor antagonist | 0.096 0.028 DBMET03759 | DBMET03759 | |
| 0.001 | 0.965 | 0.076 | Histamine H1 receptor antagonist | 0.076 0.062 DBMET03758 | DBMET03758 | |
| 0.002 | 0.968 | 0.116 | Nav1.6 sodium channel blocker | 0.116 0.102 DBMET03758 | DBMET03758 | |
| 0 | 0.966 | 0.042 | Alpha 1d adrenoreceptor agonist | 0.042 0.023 DBMET03758 | DBMET03758 | |
| 0.001 | 0.967 | 0.184 | MAP kinase kinase inhibitor | 0.184 0.034 DBMET03759 | DBMET03759 | |
| 0.002 | 0.968 | 0.109 | Beta amyloid protein antagonist | 0.109 0.079 DBMET03759 | DBMET03759 | |
| 0.004 | 0.97 | 0.203 | Histone acetyltransferase inhibitor | 0.166 0.118 DBMET03758 0.203 0.065 DBMET03759 | DBMET03759 | |
| 0.001 | 0.968 | 0.303 | MAP kinase kinase 2 inhibitor | 0.303 0.034 DBMET03759 | DBMET03759 | |
| 0.01 | 0.976 | 0.167 | Heat shock protein 70 antagonist | 0.135 0.095 DBMET03758 0.167 0.02 DBMET03759 | DBMET03759 | |
| 0.002 | 0.969 | 0.13 | Interleukin 1 beta converting enzyme inhibitor | 0.13 0.028 DBMET03759 | DBMET03759 | |
| 0.001 | 0.968 | 0.057 | Thromboxane synthase inhibitor | 0.057 0.032 DBMET03759 | DBMET03759 | |
| 0.001 | 0.969 | 0.234 | Pyruvate kinase inhibitor | 0.234 0.066 DBMET03759 | DBMET03759 | |
| 0.001 | 0.968 | 0.081 | mTOR inhibitor | 0.081 0.017 DBMET03758 | DBMET03758 | |
| 0.017 | 0.984 | 0.259 | Nitric-oxide synthase stimulant | 0.182 0.124 DBMET03758 0.259 0.027 DBMET03759 | DBMET03759 | |
| 0 | 0.969 | 0.071 | 5 Hydroxytryptamine 3A antagonist | 0.071 0.041 DBMET03758 | DBMET03758 | |
| 0.001 | 0.97 | 0.162 | I kappa B kinase inhibitor | 0.162 0.013 DBMET03759 | DBMET03759 | |
| 0.001 | 0.97 | 0.095 | Bromodomain-containing protein 2 inhibitor | 0.095 0.047 DBMET03758 | DBMET03758 | |
| 0.002 | 0.971 | 0.195 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.195 0.076 DBMET03759 | DBMET03759 | |
| 0.001 | 0.97 | 0.064 | Protein kinase (CK2) beta inhibitor | 0.064 0.005 DBMET03759 | DBMET03759 | |
| 0.004 | 0.974 | 0.175 | CF transmembrane conductance regulator agonist | 0.175 0.041 DBMET03759 | DBMET03759 | |
| 0.001 | 0.971 | 0.112 | MAP kinase kinase 1 inhibitor | 0.112 0.043 DBMET03759 | DBMET03759 | |
| 0.003 | 0.973 | 0.186 | MAP kinase 3 inhibitor | 0.186 0.031 DBMET03759 | DBMET03759 | |
| 0.005 | 0.976 | 0.151 | Phospholipase C inhibitor | 0.151 0.104 DBMET03759 | DBMET03759 | |
| 0.001 | 0.972 | 0.07 | I kappa B kinase 2 inhibitor | 0.07 0.032 DBMET03759 | DBMET03759 | |
| 0.001 | 0.972 | 0.127 | Alcohol dehydrogenase inhibitor | 0.127 0.03 DBMET03759 | DBMET03759 | |
| 0 | 0.972 | 0.04 | Potassium channel small-conductance Ca-activated activator | 0.04 0.015 DBMET03758 | DBMET03758 | |
| 0.001 | 0.973 | 0.054 | Botulinum neurotoxin type A inhibitor | 0.054 0.048 DBMET03759 | DBMET03759 | |
| 0 | 0.973 | 0.04 | DNA gyrase subunit B inhibitor | 0.04 0.023 DBMET03759 | DBMET03759 | |
| 0.001 | 0.973 | 0.082 | Glutamate (mGluR group III) agonist | 0.082 0.013 DBMET03759 | DBMET03759 | |
| 0.003 | 0.976 | 0.123 | Interleukin 8 antagonist | 0.123 0.058 DBMET03759 | DBMET03759 | |
| 0.002 | 0.976 | 0.115 | Potassium channel (Ca-activated) activator | 0.115 0.044 DBMET03759 | DBMET03759 | |
| 0.001 | 0.975 | 0.072 | Adenosine deaminase inhibitor | 0.072 0.012 DBMET03759 | DBMET03759 | |
| 0.001 | 0.974 | 0.116 | Activin receptor-like kinase 2 inhibitor | 0.116 0.101 DBMET03758 | DBMET03758 | |
| 0 | 0.974 | 0.041 | Retinoid X alpha receptor agonist | 0.041 0.019 DBMET03759 | DBMET03759 | |
| 0.001 | 0.975 | 0.095 | Nicotinic acid receptor agonist | 0.095 0.005 DBMET03759 | DBMET03759 | |
| 0.001 | 0.975 | 0.177 | Cyclin-dependent kinase 8 inhibitor | 0.177 0.054 DBMET03758 0.175 0.056 DBMET03759 | DBMET03758 | |
| 0.001 | 0.975 | 0.049 | Heparanase inhibitor | 0.049 0.048 DBMET03759 | DBMET03759 | |
| 0 | 0.975 | 0.039 | Glutamate (mGluR4) agonist | 0.039 0.016 DBMET03759 | DBMET03759 | |
| 0 | 0.975 | 0.023 | Cyclin T1 inhibitor | 0.023 0.008 DBMET03759 | DBMET03759 | |
| 0 | 0.975 | 0.022 | Prostaglandin H2 antagonist | 0.022 0.021 DBMET03759 | DBMET03759 | |
| 0.008 | 0.983 | 0.205 | 5 Hydroxytryptamine 3E antagonist | 0.205 0.054 DBMET03758 | DBMET03758 | |
| 0.001 | 0.976 | 0.168 | Mannose-6-phosphate isomerase inhibitor | 0.168 0.051 DBMET03759 | DBMET03759 | |
| 0 | 0.976 | 0.027 | 5 Hydroxytryptamine 6 agonist | 0.027 0.023 DBMET03758 | DBMET03758 | |
| 0.002 | 0.979 | 0.223 | Non-steroidal antiinflammatory agent | 0.223 0.056 DBMET03759 | DBMET03759 | |
| 0.011 | 0.988 | 0.09 | Glutamate release inhibitor | 0.09 0.062 DBMET03759 | DBMET03759 | |
| 0.002 | 0.979 | 0.061 | Topoisomerase II beta inhibitor | 0.061 0.021 DBMET03759 | DBMET03759 | |
| 0.001 | 0.979 | 0.066 | 5 Hydroxytryptamine 3 agonist | 0.066 0.04 DBMET03758 | DBMET03758 | |
| 0 | 0.978 | 0.031 | Retinoid X receptor agonist | 0.031 0.029 DBMET03759 | DBMET03759 | |
| 0 | 0.979 | 0.075 | Mannitol-1-phosphate 5-dehydrogenase inhibitor | 0.068 0.027 DBMET03758 0.075 0.023 DBMET03759 | DBMET03759 | |
| 0.001 | 0.98 | 0.076 | Protein kinase C beta inhibitor | 0.076 0.036 DBMET03759 | DBMET03759 | |
| 0 | 0.979 | 0.045 | Glutamate (mGluR3) antagonist | 0.045 0.016 DBMET03759 | DBMET03759 | |
| 0.001 | 0.979 | 0.187 | Focal adhesion kinase 2 inhibitor | 0.187 0.081 DBMET03759 | DBMET03759 | |
| 0 | 0.98 | 0.043 | Thymidylate synthase inhibitor | 0.043 0.037 DBMET03759 | DBMET03759 | |
| 0 | 0.98 | 0.048 | Acetylcholine M1 receptor agonist | 0.048 0.027 DBMET03758 | DBMET03758 | |
| 0.003 | 0.982 | 0.135 | Transcription factor STAT6 inhibitor | 0.135 0.038 DBMET03759 | DBMET03759 | |
| 0 | 0.98 | 0.082 | S-adenosyl-L-methionine decarboxylase inhibitor | 0.082 0.034 DBMET03759 | DBMET03759 | |
| 0.005 | 0.985 | 0.591 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.403 0.098 DBMET03758 0.591 0.008 DBMET03759 | DBMET03759 | |
| 0.004 | 0.985 | 0.277 | RNA-directed DNA polymerase inhibitor | 0.247 0.051 DBMET03758 0.277 0.037 DBMET03759 | DBMET03759 | |
| 0.001 | 0.981 | 0.024 | Glutamate (mGluR1) agonist | 0.024 0.018 DBMET03759 | DBMET03759 | |
| 0 | 0.981 | 0.088 | Dihydroorotase inhibitor | 0.088 0.007 DBMET03759 | DBMET03759 | |
| 0 | 0.981 | 0.049 | Methionyl aminopeptidase 1 inhibitor | 0.049 0.007 DBMET03759 | DBMET03759 | |
| 0.001 | 0.982 | 0.126 | DOPA decarboxylase inhibitor | 0.126 0.039 DBMET03759 | DBMET03759 | |
| 0.003 | 0.984 | 0.197 | Hexokinase inhibitor | 0.197 0.037 DBMET03759 | DBMET03759 | |
| 0.001 | 0.982 | 0.067 | Phosphodiesterase 1A inhibitor | 0.067 0.028 DBMET03758 | DBMET03758 | |
| 0.002 | 0.983 | 0.078 | mTOR complex 2 inhibitor | 0.078 0.073 DBMET03759 | DBMET03759 | |
| 0.001 | 0.983 | 0.178 | GABA C receptor antagonist | 0.178 0.018 DBMET03759 | DBMET03759 | |
| 0.001 | 0.983 | 0.026 | Hedgehog signaling activator | 0.026 0.022 DBMET03759 | DBMET03759 | |
| 0.001 | 0.983 | 0.058 | Phosphodiesterase 1B inhibitor | 0.058 0.044 DBMET03758 | DBMET03758 | |
| 0 | 0.983 | 0.024 | Integrin alpha2beta1 antagonist | 0.024 0.022 DBMET03759 | DBMET03759 | |
| 0.001 | 0.984 | 0.069 | Dihydroorotate oxidase inhibitor | 0.069 0.018 DBMET03759 | DBMET03759 | |
| 0.001 | 0.984 | 0.133 | Sphingosine 1-phosphate receptor 5 antagonist | 0.133 0.093 DBMET03759 | DBMET03759 | |
| 0.002 | 0.985 | 0.156 | Cytokine production inhibitor | 0.156 0.057 DBMET03759 | DBMET03759 | |
| 0.001 | 0.984 | 0.087 | Acetylcholine agonist | 0.087 0.058 DBMET03758 | DBMET03758 | |
| 0 | 0.984 | 0.062 | Acetylcholine muscarinic agonist | 0.062 0.032 DBMET03758 | DBMET03758 | |
| 0.005 | 0.988 | 0.312 | Calcium channel activator | 0.312 0.08 DBMET03759 | DBMET03759 | |
| 0.001 | 0.984 | 0.069 | Glutamate (mGluR group III) antagonist | 0.069 0.009 DBMET03759 | DBMET03759 | |
| 0 | 0.984 | 0.027 | Nicotinic acid receptor 1 antagonist | 0.027 0.005 DBMET03759 | DBMET03759 | |
| 0.001 | 0.984 | 0.136 | Cytidine deaminase inhibitor | 0.136 0.087 DBMET03759 | DBMET03759 | |
| 0.002 | 0.986 | 0.159 | Antipruritic | 0.159 0.084 DBMET03759 | DBMET03759 | |
| 0 | 0.984 | 0.065 | Nerve growth factor antagonist | 0.065 0.007 DBMET03759 | DBMET03759 | |
| 0 | 0.985 | 0.036 | Nicotinic acid receptor 2 antagonist | 0.036 0.007 DBMET03759 | DBMET03759 | |
| 0.001 | 0.986 | 0.192 | GABA C receptor rho-2 antagonist | 0.192 0.034 DBMET03758 0.191 0.034 DBMET03759 | DBMET03758 | |
| 0 | 0.985 | 0.298 | Porphobilinogen synthase inhibitor | 0.298 0.005 DBMET03759 | DBMET03759 | |
| 0.002 | 0.987 | 0.231 | Cyclic AMP phosphodiesterase inhibitor | 0.231 0.074 DBMET03759 | DBMET03759 | |
| 0.001 | 0.986 | 0.046 | Cytokine production stimulant | 0.046 0.042 DBMET03758 | DBMET03758 | |
| 0.001 | 0.986 | 0.153 | Protein kinase C gamma inhibitor | 0.108 0.065 DBMET03758 0.153 0.03 DBMET03759 | DBMET03759 | |
| 0 | 0.986 | 0.105 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | 0.105 0.003 DBMET03759 | DBMET03759 | |
| 0.001 | 0.987 | 0.482 | GABA C receptor rho-3 antagonist | 0.482 0.031 DBMET03758 0.394 0.064 DBMET03759 | DBMET03758 | |
| 0.001 | 0.987 | 0.087 | Glutamate (mGluR4) antagonist | 0.087 0.007 DBMET03759 | DBMET03759 | |
| 0 | 0.986 | 0.099 | Acyl-CoA dehydrogenase inhibitor | 0.099 0.017 DBMET03759 | DBMET03759 | |
| 0.001 | 0.988 | 0.131 | Glutamate dehydrogenase inhibitor | 0.131 0.02 DBMET03759 | DBMET03759 | |
| 0.003 | 0.99 | 0.2 | Vasodilator, coronary | 0.2 0.182 DBMET03759 | DBMET03759 | |
| 0 | 0.987 | 0.054 | Carbamoyl phosphate synthetase inhibitor | 0.054 0.05 DBMET03759 | DBMET03759 | |
| 0 | 0.987 | 0.099 | Dihydropteroate synthase inhibitor | 0.099 0.005 DBMET03759 | DBMET03759 | |
| 0.001 | 0.988 | 0.098 | Granulocyte macrophage colony stimulating factor agonist | 0.098 0.038 DBMET03759 | DBMET03759 | |
| 0.002 | 0.989 | 0.113 | TRPA1 agonist | 0.113 0.067 DBMET03759 | DBMET03759 | |
| 0.002 | 0.989 | 0.162 | DNA damaging | 0.162 0.155 DBMET03759 | DBMET03759 | |
| 0 | 0.987 | 0.01 | Imidazoline I2 receptor antagonist | 0.01 0.009 DBMET03758 | DBMET03758 | |
| 0.001 | 0.988 | 0.056 | Immunoglobulin Fc receptor antagonist | 0.056 0.034 DBMET03759 | DBMET03759 | |
| 0.001 | 0.988 | 0.075 | GABA B receptor agonist | 0.075 0.054 DBMET03759 | DBMET03759 | |
| 0 | 0.988 | 0.314 | Ferrochelatase inhibitor | 0.314 0.006 DBMET03759 | DBMET03759 | |
| 0 | 0.988 | 0.163 | Aconitate hydratase inhibitor | 0.163 0.004 DBMET03759 | DBMET03759 | |
| 0.002 | 0.99 | 0.143 | Carbonic anhydrase III inhibitor | 0.143 0.031 DBMET03759 | DBMET03759 | |
| 0 | 0.988 | 0.031 | Acid ceramidase inhibitor | 0.031 0.008 DBMET03758 | DBMET03758 | |
| 0 | 0.988 | 0.107 | Glutamate (mGluR7) antagonist | 0.107 0.007 DBMET03758 0.086 0.021 DBMET03759 | DBMET03758 | |
| 0.001 | 0.989 | 0.137 | NADH dehydrogenase inhibitor | 0.137 0.021 DBMET03759 | DBMET03759 | |
| 0.004 | 0.992 | 0.145 | Interferon gamma antagonist | 0.145 0.084 DBMET03759 | DBMET03759 | |
| 0 | 0.989 | 0.05 | Phosphoglycerate kinase inhibitor | 0.05 0.014 DBMET03759 | DBMET03759 | |
| 0 | 0.989 | 0.013 | Integrin alphaVbeta5 antagonist | 0.013 0.005 DBMET03759 | DBMET03759 | |
| 0.001 | 0.99 | 0.093 | D-Ala-D-Ala ligase inhibitor | 0.093 0.039 DBMET03759 | DBMET03759 | |
| 0 | 0.989 | 0.176 | Phenylalanine 4-hydroxylase inhibitor | 0.176 0.009 DBMET03759 | DBMET03759 | |
| 0.001 | 0.99 | 0.12 | Purinergic P2X1 antagonist | 0.12 0.011 DBMET03759 | DBMET03759 | |
| 0.001 | 0.99 | 0.109 | Cathepsin H inhibitor | 0.109 0.092 DBMET03759 | DBMET03759 | |
| 0.002 | 0.991 | 0.155 | Adenylate kinase inhibitor | 0.155 0.024 DBMET03759 | DBMET03759 | |
| 0.001 | 0.99 | 0.108 | Sphingosine 1-phosphate receptor 4 antagonist | 0.108 0.1 DBMET03759 | DBMET03759 | |
| 0 | 0.99 | 0.146 | Histamine N-methyltransferase inhibitor | 0.146 0.015 DBMET03759 | DBMET03759 | |
| 0 | 0.99 | 0.071 | Catalase inhibitor | 0.071 0.054 DBMET03759 | DBMET03759 | |
| 0 | 0.99 | 0.224 | Alcohol oxidase inhibitor | 0.224 0.005 DBMET03759 | DBMET03759 | |
| 0.001 | 0.991 | 0.251 | Insulysin inhibitor | 0.251 0.095 DBMET03759 | DBMET03759 | |
| 0.001 | 0.991 | 0.305 | Peroxidase inhibitor | 0.305 0.036 DBMET03759 | DBMET03759 | |
| 0.003 | 0.993 | 0.281 | Gastrin inhibitor | 0.281 0.047 DBMET03759 | DBMET03759 | |
| 0 | 0.991 | 0.038 | Tryptophan 5 hydroxylase inhibitor | 0.038 0.019 DBMET03759 | DBMET03759 | |
| 0 | 0.991 | 0.155 | Biliverdin reductase inhibitor | 0.155 0.009 DBMET03759 | DBMET03759 | |
| 0 | 0.991 | 0.019 | Imidazoline I1 receptor antagonist | 0.019 0.017 DBMET03758 | DBMET03758 | |
| 0.002 | 0.993 | 0.268 | Transcription factor STAT inhibitor | 0.268 0.075 DBMET03759 | DBMET03759 | |
| 0.001 | 0.992 | 0.12 | Acetylcholine release stimulant | 0.12 0.048 DBMET03758 0.1 0.088 DBMET03759 | DBMET03758 | |
| 0 | 0.991 | 0.109 | Creatine kinase inhibitor | 0.109 0.05 DBMET03759 | DBMET03759 | |
| 0 | 0.991 | 0.036 | Fumarate hydratase inhibitor | 0.036 0.022 DBMET03759 | DBMET03759 | |
| 0 | 0.991 | 0.034 | Acetylcholine M4 receptor agonist | 0.034 0.018 DBMET03758 | DBMET03758 | |
| 0.005 | 0.996 | 0.578 | Histamine release inhibitor | 0.367 0.092 DBMET03758 0.578 0.012 DBMET03759 | DBMET03759 | |
| 0.002 | 0.993 | 0.169 | Antiamyloidogenic | 0.169 0.124 DBMET03759 | DBMET03759 | |
| 0 | 0.992 | 0.095 | 5 Hydroxytryptamine 3A agonist | 0.095 0.082 DBMET03758 | DBMET03758 | |
| 0.001 | 0.993 | 0.155 | Ca2+-transporting ATPase inhibitor | 0.133 0.104 DBMET03758 0.155 0.033 DBMET03759 | DBMET03759 | |
| 0.001 | 0.993 | 0.127 | Triose-phosphate isomerase inhibitor | 0.127 0.028 DBMET03759 | DBMET03759 | |
| 0.002 | 0.994 | 0.519 | 5 Hydroxytryptamine release inhibitor | 0.266 0.206 DBMET03758 0.519 0.027 DBMET03759 | DBMET03759 | |
| 0 | 0.992 | 0.054 | Ornithine carbamoyltransferase inhibitor | 0.054 0.036 DBMET03759 | DBMET03759 | |
| 0 | 0.992 | 0.152 | UDP-glucose 4-epimerase inhibitor | 0.152 0.028 DBMET03759 | DBMET03759 | |
| 0.001 | 0.993 | 0.204 | Insulin sensitizer | 0.204 0.07 DBMET03759 | DBMET03759 | |
| 0 | 0.993 | 0.078 | Nicotinic alpha4beta2 receptor antagonist | 0.078 0.052 DBMET03758 | DBMET03758 | |
| 0 | 0.993 | 0.052 | Lysophosphatidic acid 3 receptor antagonist | 0.052 0.033 DBMET03759 | DBMET03759 | |
| 0 | 0.993 | 0.141 | Arachidonic acid antagonist | 0.141 0.099 DBMET03759 | DBMET03759 | |
| 0 | 0.993 | 0.209 | GABA C receptor rho-1 antagonist | 0.092 0.074 DBMET03758 0.209 0.007 DBMET03759 | DBMET03759 | |
| 0 | 0.993 | 0.082 | Argininosuccinate synthase inhibitor | 0.082 0.025 DBMET03759 | DBMET03759 | |
| 0.005 | 0.998 | 0.169 | 5 Hydroxytryptamine release stimulant | 0.169 0.153 DBMET03758 | DBMET03758 | |
| 0.001 | 0.994 | 0.333 | Superoxide dismutase inhibitor | 0.333 0.041 DBMET03759 | DBMET03759 | |
| 0.001 | 0.994 | 0.092 | Phosphodiesterase 6D inhibitor | 0.089 0.08 DBMET03758 0.092 0.071 DBMET03759 | DBMET03759 | |
| 0.001 | 0.993 | 0.089 | Carbonic anhydrase XIII inhibitor | 0.089 0.044 DBMET03759 | DBMET03759 | |
| 0.001 | 0.994 | 0.092 | Keratolytic | 0.092 0.036 DBMET03759 | DBMET03759 | |
| 0.001 | 0.994 | 0.126 | Mucolytic | 0.126 0.049 DBMET03759 | DBMET03759 | |
| 0 | 0.993 | 0.369 | GABA C receptor agonist | 0.369 0.006 DBMET03759 | DBMET03759 | |
| 0 | 0.994 | 0.15 | Electrolyte absorption antagonist | 0.15 0.019 DBMET03759 | DBMET03759 | |
| 0.003 | 0.996 | 0.314 | Caspase 9 stimulant | 0.305 0.188 DBMET03758 0.314 0.179 DBMET03759 | DBMET03759 | |
| 0.001 | 0.994 | 0.213 | Neurotrophic factor enhancer | 0.213 0.065 DBMET03758 0.186 0.091 DBMET03759 | DBMET03758 | |
| 0 | 0.994 | 0.134 | Phosphofructokinase-1 inhibitor | 0.134 0.021 DBMET03759 | DBMET03759 | |
| 0.002 | 0.996 | 0.289 | 5 Hydroxytryptamine uptake stimulant | 0.199 0.154 DBMET03758 0.289 0.051 DBMET03759 | DBMET03759 | |
| 0 | 0.994 | 0.042 | GABA uptake inhibitor | 0.042 0.024 DBMET03759 | DBMET03759 | |
| 0.002 | 0.995 | 0.204 | Antithrombotic | 0.204 0.173 DBMET03759 | DBMET03759 | |
| 0 | 0.994 | 0.069 | Glutamate (mGluR6) antagonist | 0.069 0.041 DBMET03759 | DBMET03759 | |
| 0.004 | 0.997 | 0.186 | Interleukin agonist | 0.186 0.134 DBMET03759 | DBMET03759 | |
| 0 | 0.994 | 0.169 | Cystathionine beta-synthase inhibitor | 0.096 0.082 DBMET03758 0.169 0.033 DBMET03759 | DBMET03759 | |
| 0.001 | 0.995 | 0.141 | Aminopeptidase B inhibitor | 0.141 0.042 DBMET03759 | DBMET03759 | |
| 0.002 | 0.995 | 0.289 | DNA synthesis inhibitor | 0.249 0.067 DBMET03758 0.289 0.048 DBMET03759 | DBMET03759 | |
| 0 | 0.994 | 0.031 | Glutamate (mGluR3) agonist | 0.031 0.025 DBMET03759 | DBMET03759 | |
| 0.001 | 0.994 | 0.098 | MAP kinase kinase 7 inhibitor | 0.098 0.015 DBMET03759 | DBMET03759 | |
| 0.002 | 0.996 | 0.291 | Vasodilator, peripheral | 0.291 0.102 DBMET03759 | DBMET03759 | |
| 0 | 0.994 | 0.043 | Glutamate (mGluR8) agonist | 0.043 0.017 DBMET03759 | DBMET03759 | |
| 0.001 | 0.995 | 0.096 | Expectorant | 0.096 0.073 DBMET03759 | DBMET03759 | |
| 0.001 | 0.995 | 0.102 | HIV-1 integrase (Overall Integration) inhibitor | 0.102 0.053 DBMET03759 | DBMET03759 | |
| 0.001 | 0.996 | 0.132 | Tumour necrosis factor antagonist | 0.132 0.124 DBMET03759 | DBMET03759 | |
| 0.001 | 0.996 | 0.168 | Spasmolytic | 0.168 0.147 DBMET03758 | DBMET03758 | |
| 0 | 0.995 | 0.08 | Nicotinic receptor alpha7 subunit antagonist | 0.08 0.017 DBMET03758 | DBMET03758 | |
| 0.001 | 0.996 | 0.074 | Carbonic anhydrase VI inhibitor | 0.074 0.066 DBMET03759 | DBMET03759 | |
| 0.001 | 0.996 | 0.289 | Transcription factor NF kappa B inhibitor | 0.289 0.1 DBMET03759 | DBMET03759 | |
| 0 | 0.995 | 0.121 | Histidine decarboxylase inhibitor | 0.121 0.025 DBMET03759 | DBMET03759 | |
| 0.001 | 0.996 | 0.127 | Adenylate cyclase stimulant | 0.127 0.109 DBMET03759 | DBMET03759 | |
| 0.001 | 0.996 | 0.162 | Anesthetic general | 0.162 0.102 DBMET03759 | DBMET03759 | |
| 0 | 0.996 | 0.418 | Alpha-N-acetylglucosaminidase inhibitor | 0.418 0.008 DBMET03759 | DBMET03759 | |
| 0 | 0.996 | 0.089 | GABA aminotransferase inhibitor | 0.089 0.037 DBMET03759 | DBMET03759 | |
| 0 | 0.995 | 0.078 | NMDA receptor glycine site agonist | 0.078 0.03 DBMET03759 | DBMET03759 | |
| 0 | 0.996 | 0.094 | NMDA receptor agonist | 0.094 0.022 DBMET03759 | DBMET03759 | |
| 0.001 | 0.996 | 0.124 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.124 0.037 DBMET03759 | DBMET03759 | |
| 0 | 0.996 | 0.098 | Aminopeptidase I inhibitor | 0.098 0.029 DBMET03759 | DBMET03759 | |
| 0 | 0.996 | 0.048 | Kainate receptor agonist | 0.048 0.017 DBMET03759 | DBMET03759 | |
| 0 | 0.996 | 0.109 | Glutamate decarboxylase inhibitor | 0.109 0.025 DBMET03759 | DBMET03759 | |
| 0 | 0.996 | 0.345 | Aldehyde oxidase inhibitor | 0.345 0.056 DBMET03759 | DBMET03759 | |
| 0 | 0.996 | 0.063 | Neuronal nicotinic receptor antagonist | 0.063 0.052 DBMET03758 | DBMET03758 | |
| 0 | 0.997 | 0.111 | Carbonic anhydrase XV inhibitor | 0.111 0.054 DBMET03759 | DBMET03759 | |
| 0.001 | 0.997 | 0.196 | Tyrosine 3 hydroxylase inhibitor | 0.188 0.159 DBMET03758 0.196 0.144 DBMET03759 | DBMET03759 | |
| 0 | 0.997 | 0.207 | Succinate dehydrogenase inhibitor | 0.207 0.043 DBMET03759 | DBMET03759 | |
| 0 | 0.997 | 0.032 | Arginase inhibitor | 0.032 0.029 DBMET03759 | DBMET03759 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |